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Genetic variation at MECOM, TERT, JAK2 and
HBS1L-MYB predisposes to myeloproliferative
neoplasms
William Tapper1,2,*, Amy V. Jones1,2,*, Robert Kralovics3, Ashot S. Harutyunyan3, Katerina Zoi4, William Leung1,2,
Anna L. Godfrey5,6, Paola Guglielmelli7, Alison Callaway2, Daniel Ward2, Paula Aranaz2, Helen E. White1,2,
Katherine Waghorn1,2, Feng Lin1,2, Andrew Chase1,2, E. Joanna Baxter5,6, Cathy Maclean5,6, Jyoti Nangalia5,6,
Edwin Chen5,6, Paul Evans8, Michael Short8, Andrew Jack8, Louise Wallis9, David Oscier9, Andrew S. Duncombe10,
Anna Schuh11, Adam J. Mead12, Michael Grifﬁths13,14, Joanne Ewing15, Rosemary E. Gale16, Susanne Schnittger17,
Torsten Haferlach17, Frank Stegelmann18, Konstanze Do¨hner18, Harald Grallert19,20, Konstantin Strauch19,21,
Toshiko Tanaka22, Stefania Bandinelli23, Andreas Giannopoulos4, Lisa Pieri7, Carmela Mannarelli7, Heinz Gisslinger24,
Giovanni Barosi25, Mario Cazzola26,27, Andreas Reiter28, Claire Harrison29, Peter Campbell30, Anthony R. Green5,6,
Alessandro Vannucchi7 & Nicholas C.P. Cross1,2
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2,
CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage
genome-wide association study of 3,437 MPN cases and 10,083 controls, we identify two SNPs
with genome-wide signiﬁcance in JAK2V617F-negative MPN: rs12339666 (JAK2; meta-analysis
P¼ 1.27 10 10) and rs2201862 (MECOM; meta-analysis P¼ 1.96 10 9). Two additional SNPs,
rs2736100 (TERT) and rs9376092 (HBS1L/MYB), achieve genome-wide signiﬁcance when
including JAK2V617F-positive cases. rs9376092 has a stronger effect in JAK2V617F-negative cases
with CALR and/or MPL mutations (Breslow–Day P¼4.5 10 7), whereas in JAK2V617F-positive
cases rs9376092 associates with essential thrombocythemia (ET) rather than polycythemia vera
(allelic w2 P¼ 7.3 10 7). Reduced MYB expression, previously linked to development of an
ET-like disease in model systems, associates with rs9376092 in normal myeloid cells. These
ﬁndings demonstrate that multiple germline variants predispose to MPN and link constitutional
differences in MYB expression to disease phenotype.
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M
yeloproliferative neoplasms (MPN) are a group of
related haematological disorders that are characterized by
an excess proliferation of one or more myeloid cell
lineages and a tendency to transform to acute myeloid leukaemia1.
MPNs are classiﬁed by which myeloid cell lineage(s) is
predominantly expanded in the peripheral blood, namely
erythrocytes in polycythemia vera (PV) and platelets in essential
thrombocythemia (ET). Patients with primary myeloﬁbrosis (PMF)
display bone marrow ﬁbrosis, megakaryocytic abnormalities,
variable peripheral blood counts, extramedullary haematopoiesis
and hepatosplenomegaly. MPNs arise as a consequence of clonal
proliferation driven by at least one somatically acquired
driver mutation. Of these, the most recurrent is JAK2V617F,
which occurs in 495% of PV and 50–60% of ET and PMF cases.
In patients without JAK2 mutations, somatic mutations in CALR
are the most common, occurring in well over 50% of JAK2V617F-
negative ET and PMF. Other somatic mutations in MPN have been
identiﬁed but they are less common and occur in fewer than 20% of
cases. Most prominent of these from a phenotypic perspective are
mutations that activate the thrombopoietin receptor (MPL), which
are seen in 3–10% of ET and PMF. In the great majority of cases,
mutations in JAK2, CALR and MPL are mutually exclusive,
although occasional cases may test positive for mutations in more
than one of these genes. Patients with ET and PMF that test
negative for JAK2, CALR and MPL mutations are typically referred
to as ‘triple negative’2,3.
Although it is accepted that acquisition of these mutations
drives clonal proliferation in MPNs, less is known about what
factors inﬂuence the development, phenotype and severity of
disease. Evidence from epidemiological4 and familial studies5,6
strongly suggest that common, low penetrance factors present in
the general population contribute to the risk of developing MPN
and potentially such factors may also contribute to the
phenotypic pleiotrophy observed in these disorders. We
previously characterized a major predisposition locus at the
JAK2 gene, which is associated with the acquisition of V617F
mutations7,8. This speciﬁc JAK2 haplotype, called ‘46/1’ or
‘GGCC’ strongly predisposes to JAK2V617F-positive disease
(OR¼ 3.7; Fisher’s exact test Po10 20). The 46/1 haplotype is
also weakly associated with JAK2 exon 12 positive PV9,
MPN with MPL W515 mutations and those that lack JAK2 or
MPL mutations10. More recently, a common germline variant
was identiﬁed in TERT, which predisposes equally to PV
(OR¼ 2.3, allelic w2 P¼ 1.1 10 5), ET (OR¼ 2.3, allelic w2
P¼ 2.87 10 3) and PMF (OR¼ 2.4, allelic w2 P¼ 2.46 10 2)
in the Icelandic population11.
Overall, the 46/1 haplotype has been estimated to account for
B50% of the population attributable risk (PAR) of developing an
MPN in European populations, but it only explains a minor
component of JAK2V617F-negative disease7. The variant in TERT
is also estimated to have a PAR of 58% in Icelandics and
contributes to JAK2V617F positive and negative disease. Since the
bulk of the population-level predisposition to JAK2V617F positive
MPN is likely to be accounted for by variation at JAK2 and TERT,
the initial aim of this study is to identify additional germline
variants that predispose to JAK2V617F-negative ET or PMF by
performing a genome-wide association study (GWAS).
We identify two single-nucleotide polymorphisms (SNPs),
rs12339666 within JAK2 and rs2201862, 153 kb downstream of
MECOM, which associate with JAK2V617F-negative disease, and
two additional SNPs, rs2736100 in TERT and rs9376092 between
HBS1L and MYB, when including JAK2V617F-positive cases. The
SNP between HBS1L and MYB, rs9376092, has a stronger effect
in JAK2V617F-negative cases with somatic CALR and/or MPL
mutations and predisposes to essential thrombocythemia in
JAK2V617F-positive cases. Finally, we demonstrate that the
candidate risk allele at rs9376092 is associated with reduced
MYB expression in normal myeloid cells.
Results
Genome-wide association study. Following quality control there
were 524 JAK2V617F-negative MPN cases, 2,674 controls and
2,098,039 SNPs (642,633 observed and 1,455,406 imputed) for
analysis at stage-1 (Supplementary Fig. 1). This cohort is esti-
mated to have 80% power for detecting common SNPs (minor
allele frequency (MAF)¼ 0.3) with relative risks of 1.25 and rare
SNPs (MAF¼ 0.05) with relative risks (RR) of 1.5 (ref. 12). The
QQ plot demonstrated good agreement between observed and
expected P values (genomic inﬂation factor, l¼ 1) until the tail of
the distribution where SNPs with P valueso10 4 deviated from
the null distribution (Supplementary Fig. 2). Systematic biases
between cases and controls such as population stratiﬁcation or
somatic mutations in the MPN cases are therefore unlikely to
contribute to the signiﬁcance of SNPs. Figure 1 shows a Man-
hattan plot of these results. Following our selection criteria
(see Methods), 203 SNPs from 173 genomic regions with allelic w2
P values r0.02 (Supplementary Table 1) were chosen for
assessment in the three-stage two cohorts.
Replication and validation of candidate SNPs. For replication at
stage-2, 196 of the 203 selected SNPs were successfully genotyped
in 658 JAK2V617F-negative MPN cases and 1,196 controls
(Supplementary Table 1). A further three SNPs were removed due
to signiﬁcant deviation from Hardy–Weinberg equilibrium
(HWE; exact test P-value r0.001 in controls) leaving 193 SNPs
for analysis. Additional cases from Germany (n¼ 187) and
Austria (n¼ 99) and controls from the BBC (n¼ 2706) and from
Bavaria (n¼ 1805), all of which had been previously genotyped,
were also used. These cases and controls were analysed as three
separate cohorts consisting of samples from the United Kingdom
(stage-2.1), Germany and Austria (stage-2.2), and Greece (stage-
2.3). After testing for allelic association and using a ﬁxed effects
meta-analysis to combine evidence from stages 1 and 2, ﬁve SNPs
were identiﬁed with combined P values r0.001 and signiﬁcant
replication in at least one of the three replication cohorts with
effects in the same direction as the stage-1 analysis
(Supplementary Table 1). The uncombined replication P-values
for allelic w2 tests ranged from 0.025 to 0.00025. One of these
SNPs (rs12339666) is located within the JAK2 gene and was not
considered further because of its consistency with previous
ﬁndings, showing that variants tagging the JAK2 46/1 haplotype
are associated with JAK2V617F-negative MPN10.
A total of four SNPs with replication at stage-2 were therefore
selected for further analysis (stage-3) in two independent cohorts
consisting of 328 cases and 2,800 controls from the United
Kingdom (stage-3.1) and 637 cases and 160,8 controls from Italy
(stage-3.2, Supplementary Table 1). Of the four SNPs tested, all of
which were successfully genotyped and passed quality criteria,
three (rs9376092, rs4858647 and rs2201862) had allelic w2 P
values o0.05 and effects in the same direction as the stage-1
analysis and remained signiﬁcant when considering the false
discovery rate13 to correct for the number of SNPs tested
(Supplementary Table 1). To further validate our ﬁndings, the
four SNPs were genotyped in 406 reactive cases from the United
Kingdom, which mimic MPNs and were thus considered as
negative controls. Comparison to 2,800 controls from the United
Kingdom (stage 3.3) indicated that none of the SNPs were
signiﬁcantly associated with the risk of developing a reactive
phenotype (Supplementary Table 1), thus supporting the notion
that they are speciﬁcally associated with clonal MPN.
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Following meta-analysis of the six cohorts using ﬁxed-effect
sizes, one novel SNP was identiﬁed with a genome-wide level of
signiﬁcance (rs2201862; meta-analysis P¼ 1.96 10 9), an effect
in the same direction as the discovery data, and without
signiﬁcant heterogeneity between cohorts (Table 1, Figs 2 and
3). Furthermore, rs2201862 had evidence for replication (Pr0.05
for allelic w2) in three of the ﬁve follow-up cohorts and two
unlinked SNPs (r2o0.5) that are within 100 kb are also signiﬁcant
(Pr0.05 for allelic w2-test) in one of the three replication cohorts
that were tested for these SNPs. Rs2201862 is located at
chromosome 3q26 B153 kb downstream of MECOM and 99 kb
downstream of a pseudogene EGFEM1P. In addition, two other
SNPs had moderate evidence of association (rs9376092 meta-
analysis P¼ 5.27 10 6 and rs4858647 meta-analysis P¼ 1.39
 10 5) and effects in the same direction as the discovery data
(Table 1, Fig. 2). However, for both these SNPs Cochran’s Q
statistic and the I2 statistic estimated signiﬁcant heterogeneity
between cohorts. Rs9376092 is located at 6q23, 51 kb upstream of
HBS1L and 76 kb upstream of MYB. Rs4858647 is an intergenic
SNP at 3p24, 255 kb upstream of THRB and 425 kb upstream of
RARB.
Association with variation at TERT. Following the discovery of
an association between rs2736100 in TERT at 5p15 and MPN11,
we re-examined our data for evidence of this relationship. In our
original analysis, rs2736100 was not tested at stage-1 due to its
signiﬁcant deviation from HWE in the pooled cohort of controls
from WTCCC2 (NBSþBBC P¼ 0.00096 for HWE exact test).
However, when controls from the NBS and BBC cohorts were
assessed separately the deviation from HWE did not exceed the
QC threshold of Pr0.001 (NBS P¼ 0.01, BBC P¼ 0.03 for HWE
exact test). The stage 1 data were therefore reanalysed using the
unpooled assessment of HWE, which identiﬁed rs2736100 as the
only SNP with a P valuer0.01 (P¼ 0.0004, OR¼ 1.27 for allelic
w2) in a 242-kb region, which ﬂanks the TERT locus by 100 kb.
This association was replicated in the Austrian cohort (P¼ 0.008,
OR¼ 1.49 for allelic w2), and a meta-analysis of the two cohorts
was used to estimate the ﬁnal signiﬁcance and effect size (Table 1:
meta-analysis P¼ 1.73 10 5, OR¼ 1.31). In both cohorts,
rs2736100 was not correlated with any other SNPs (r240.15),
which may account for the lack of supporting SNPs within the
TERT locus. Other JAK2V617F-negative cohorts were not tested
for rs2736100.
Table 1 | Summary of the top SNPs showing or approaching genome-wide signiﬁcant association (Po5 108) in meta-analysis.
SNP* Allelesw RAFz Gene JAK2V617F-negative cases JAK2V617F-negative and all JAK2V617F positive JAK2V617F-negative and JAK2V617F-positive
ET and MF cases
PMETA OR (CI) I
2 PAR PMETA OR (CI) I
2 PAR PMETA OR (CI) I
2 PAR
rs12339666y T/G 0.26 JAK2 1.272 10 10 1.34 (1.23–1.47) 0 17.4 2.287 10 62 1.76 (1.65–1.88) 96.2 27.5 1.748 10 20 1.43 (1.33–1.55) 53.4 21.0
rs2201862 T/C 0.48 MECOM 1.964 10 9 0.82 (0.77–0.88) 0 16.5 4.075 10 10 0.84 (0.80–0.89) 0 14.3 1.671 10 9 0.84 (0.79–0.89) 0 14.7
rs9376092 A/C 0.27 HBS1L-MYB 5.273 10 6 1.18 (1.10–1.26) 62 7.4 5.547 10 7 1.16 (1.09–1.23) 79.4 6.9 7.766 10 10 1.22 (1.14–1.30) 66.5 9.0
rs4858647 A/C 0.11 THRB-RARB 1.393 10 5 1.24 (1.13–1.37) 77 4.2 8.994 10 5 1.18 (1.09–1.29) 72.9 3.1 3.764 10 5 1.21 (1.10–1.32) 75.1 3.6
rs27361008 C/A 0.51 TERT 1.728 10 5 1.31 (1.16–1.47) 0 34.9 3.667 10 26 1.51 (1.40–1.63) 71.0 42.7 4.026 10 13 1.43 (1.31–1.57) 83.5 37.8
*rs identiﬁer from dbSNP.
wRisk-associated/non-risk-associated alleles.
zFrequency of risk allele in controls that were used to calculate population attributable risk (PAR). PMETA, ﬁxed effects meta-analysis of allelic w2 tests; OR, odds ratio; CI, 95% conﬁdence interval;
I2, heterogeneity index (0–100).
yIn JAK2V617F-negative cases, meta-analysis is based on a combination of four studies instead of six. In JAK2V617F-negative and all JAK2V617F-positive cases, meta-analysis is based on a combination of six
studies instead of eight. In JAK2V617F-negative and ET and PMF JAK2V617F-positive cases, meta-analysis is based on a combination of ﬁve studies instead of seven.
8In JAK2V617F-negative cases, meta-analysis is based on a combination of two studies instead of six. In JAK2V617F-negative and all JAK2V617F-positive cases, meta-analysis is based on a combination of
four studies instead of eight. In JAK2V617F-negative and ET and PMF JAK2V617F-positive cases, meta-analysis is based on a combination of three studies instead of seven.
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Figure 1 | Genome-wide association of JAK2V617F-negative myeloproliferative neoplasms. This Manhattan plot shows the results of the stage 1 GWAS
for all autosomes. Results are plotted as –log10 of the allelic w2 P value. At this stage, no SNPs met the stringent genome-wide signiﬁcance level of P value
r108. The three SNPs that attained genome-wide signiﬁcance and two additional SNPs with moderate association following meta-analysis are
highlighted in green, on chromosome 3 (rs2201862 and rs4858647), chromosome 5 (rs2736100), chromosome 6 (rs9376092) and chromosome 9
(rs12339666). This plot was produced using the qqman R package.
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Associations with CALR and MPL mutations. To investigate
whether the SNPs we identiﬁed had similar effects in cases with
and without somatic mutations of CALR and/or MPL, the 6
JAK2V617F-negative cohorts were stratiﬁed according to the pre-
sence or absence of these mutations and compared using a
Breslow–Day test (Table 2B). This analysis determined that the
effects of rs12339666 and rs9376092 were signiﬁcantly lower in
cases without CALR and/or MPL mutations, while rs2201862,
rs4858647 and rs2736100 had effects that were similar in cases
with and without these mutations. Of these, rs9376092 (HBS1L-
MYB) was particularly prominent (Breslow–Day P¼ 4.5 10 7;
Table 2B).
To investigate the possibility that germline variation at CALR
might contribute to the acquisition of somatic CALR mutations, a
206-kb region that ﬂanks the CALR locus by 100 kb and contains
11 SNPs was investigated in the stage 1 data as a whole and in the
subset of cases with CALR mutations. No signiﬁcant SNPs were
identiﬁed in this region in either data set (Supplementary Fig. 3).
However, the closest SNPs to CALR in this region are rs11667458,
which is 29,869 bp downstream, and rs10403210, which is
48,335 bp upstream, and neither of these are in linkage
disequilibrium (LD) with any SNPs in or close to CALR.
Additional studies are therefore required to determine deﬁnitively
whether germline variation at CALR inﬂuences the acquisition of
somatic CALR mutations.
Associations with JAK2V617F-positive MPN. To determine
whether any of the SNPs were associated exclusively with
JAK2V617F-negative MPN, two cohorts of JAK2V617F-positive
cases (PV, n¼ 505; ET, n¼ 499) and 2,706 controls from the
United Kingdom were analysed (stage-3.4 and stage 3.5). After
testing for allelic association and using the false discovery rate13
to correct for the ﬁve SNPs tested, all SNPs except rs4858647
retained signiﬁcance in at least one of the two cohorts and had
effects in the same direction as the previous analyses
(Supplementary Table 1). On comparison of JAK2V617F positive
and negative MPN, the Breslow–Day test identiﬁed two SNPs that
had stronger effects in JAK2V617F-positive cases: rs12339666
(Breslow–Day P¼ 2.8 10 18), which tags the JAK2 46/1
haplotype, and rs2736100 (TERT; Breslow–Day P¼ 0.0026).
Rs4858647 (THRB-RARB) had a stronger effect in JAK2V617F-
negative cases (Breslow–Day P¼ 0.015), and no difference was
seen for the remaining SNPs rs2201862 (MECOM) and rs9376092
(HBS1L-MYB) (Table 2B).
Comparison of effect sizes between JAK2V617F-positive ET
versus controls and JAK2V617F-positive PV versus controls
revealed signiﬁcantly larger effect for rs12339666 in PV (JAK2;
Breslow–Day P ¼ 2.452 10 11) and rs9376092 in ET (HBS1L-
MYB; Breslow–Day P¼ 0.0004; Table 2B). Meta-analysis of all
JAK2V617F-negative and JAK2V617F-positive cases (Table 1)
identiﬁed three SNPs that achieved genome-wide signiﬁcance:
rs12339666 (JAK2), rs2736100 (TERT) and rs2201862 (MECOM).
Rs9376092 (HBS1L-MYB) also achieved genome-wide signiﬁ-
cance in meta-analysis of all JAK2V617F-negative and JAK2V617F-
positive ET and MF cases (Table 1).
Population attributable risks. According to the genotypic odds
ratio and population frequency, rs2736100 is estimated to account
for the largest proportion of the population attributable risk in
JAK2V617F-negative cases (PAR¼ 34.9%) followed by
rs12339666, which tags the 46/1 haplotype (PAR¼ 17.4% com-
pared with 11.8% for the tightly linked SNP rs12340895 in
JAK2V617F and MPL mutation negative cases from our previous
study10). The SNP in close proximity to MECOM, rs2201862,
accounts for 16.5% of the PAR (Table 1). On the basis of a
multiplicative model without interaction, these three factors are
estimated to have a combined PAR of 55%.
Variation at rs9376092 correlates with MYB expression. The
candidate MPN risk SNP rs9376092 maps to the HBS1L andMYB
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Figure 2 | A plot of the stage 1 GWAs for the most signiﬁcant novel SNP (rs2201862) identiﬁed by meta-analysis. This plot shows the stage 1 results
(n¼ 524 JAK2V617F-negative cases versus n¼ 2674 controls) in a 400-kb region, which ﬂanks the most signiﬁcant SNP identiﬁed by meta-analysis
(rs2201862). SNPs are plotted as the  log10 of the allelic w2 P value. The amount of LD between rs220186 and all other SNPs is indicated by the colour of
the data points. The two SNPs with red borders (rs16853092 and rs4955627) were also genotyped and replicate at stage 2 but were not taken forward to
stage 3 because rs2201862 was more signiﬁcant at stage 2. The plot was produced using LocusZoom.
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intergenic polymorphic region (HMIP), an area that has been
linked genetically to a number of hematological traits in healthy
individuals, including platelet number14,15. Independent
functional analysis has shown that knockdown mice expressing
low levels of Myb develop a transplantable ET-like disease16. We
therefore tested whether variation at rs9376092 was linked to
differences in expression of MYB in healthy individuals. We
found that the risk allele was indeed associated with a 5.8- to9.7-
fold reduction of MYB expression in BFU-E and CFU-GM.
(Supplementary Table 2, Supplementary Fig. 4a). The risk allele
was also associated with reduced HBS1L expression, but this was
less marked (1.9- to 2.4-fold). In addition, we interrogated our
previously published gene expression data set derived from
haemopoietic colonies of MPN cases17. MYB expression in ET
was signiﬁcantly lower in JAK2V617F-heterozygous BFU-E
colonies compared with JAK2 wild-type colony cells from the
same patient (Mann–Whitney test P¼ 0.0009; q¼ 0.01), but this
difference was not seen in colonies from PV cases. For JAK2, no
difference was seen in either ET or PV (Supplementary Fig. 4b).
The other risk variants were not amenable to similar analysis
because the associated candidate genes were not sufﬁciently
expressed in PB granulocytes or colonies. Instead, we investigated
the relationship between risk alleles and the expression of
ﬂanking genes using GENEVAR and the eQTL database hosted
by the University of Chicago18. There were no correlations of any
sentinel SNP or SNP in high LD (r240.8) with gene expression
measured in lymphoblastoid cell lines.
Association with clinical features in the PT-1 trial. To deter-
mine whether variants that predispose to the development of
MPN confer a functional effect on particular aspects of MPN
disease features, we correlated genotypes of the top associations
with clinical and laboratory measurements and outcome recorded
for JAK2V617F-negative patients recruited into the PT-1 trial19
(Supplementary Table 3; absence of correlations with the JAK2
46/1 haplotype has been reported previously10). There were no
striking associations with any aspect of laboratory and clinical
features at diagnosis, but in events after trial entry, there were
weak associations of rs3737304 and rs9376092 with
transformation to myeloﬁbrosis, and venous thromboembolism
in the year before diagnosis, respectively. There was also a weak
association of rs4858647 on haemoglobin levels recorded in
response to therapy. None of these associations, however,
retained signiﬁcance after correction for multiple testing.
Discussion
We focused initially on identifying common inherited genetic
factors that predispose to JAK2V617F-negative MPN. We
analysed DNA extracted from peripheral blood leukocytes,
Cohort Size ES (95% Cl) PAR
rs12339666
rs2736100
rs2201862
rs9376092
rs4858647
UK1
UK1
UK1
UK2
UK2
UK3
UK3
Austrain and German
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Figure 3 | Forest plots and meta-analysis of genotype data for the ﬁve most signiﬁcant associations. Forest plots showing the odds ratios (OR¼ ES),
95% conﬁdence intervals (CI) and population attributable risk (PAR) of SNPs with or approaching a genome-wide level of signiﬁcance in each cohort and in
the combined analysis. The SNP subtotals show the OR and CI for a ﬁxed-effects meta-analysis and use I-squared to assess heterogeneity in effect sizes
between cohorts.
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which would be expected to include a variable proportion of
clonal and non-clonal cells. We considered the possibility that
clonal somatic changes might affect the analysis; however, in line
with previous array and exome-sequencing studies3,20 we found
that MPN genomes are relatively simple compared to other
cancers with only 8% (42/524) of cases showing likely somatic
copy-number changes or acquired uniparental disomy
(Supplementary Fig. 5). These regions of gross alteration do not
correspond to the location of the risk factors we identiﬁed and
exclusion of these cases has minimal effect on the overall results
(Supplementary Table 6). Although we cannot completely
exclude the possibility that recurrent clonal changes below the
resolution of array analysis might have inﬂuenced our ﬁndings,
SNPs in such regions would generally be excluded by our
rigorous QC criteria due to a high percentage of missing
genotypes, poor genotyping quality or deviation from HWE.
Notably, none of the associated SNPs deviated from HWE
at an Exact test P valuer0.05, which suggests that clonal changes
have not contributed to their signiﬁcance (Methods and
Supplementary Table 7).
Meta-analysis of six JAK2V617F-negative cohorts from our
three-stage GWAS identiﬁed two SNPs with genome-wide
signiﬁcance and three that approached this level of signiﬁcance.
The most signiﬁcant SNPs are rs12339666, which tags the JAK2
46/1 haplotype, and rs2201862, which is in a non-coding region
proximal to MECOM. Of the three SNPs with moderate
association, two are within or close to genes of potential
functional relevance to MPN: the intergenic region between
HBS1L and MYB and an intronic SNP in TERT, which has
recently been associated with MPN in an independent study11, as
well as several other malignancies. The remaining SNP
(rs4858647) was mapped to a gene desert on chromosome
3p24. Although the TERT SNP rs2736100 did not achieve
genome-wide signiﬁcance (Table 1), it should be noted that we
only focused on this polymorphism retrospectively and thus the
number of cases analysed was signiﬁcantly fewer than for the
other variants. When the JAK2V617F-positive cohort was included
in the analysis, rs2736100 also achieved genome-wide signiﬁcance
(Table 1).
To our knowledge, only one other polymorphism has been
reported in the literature to be associated with the development of
MPN: rs6198 in the 30 UTR of NR3C1, which encodes the
glucocorticoid receptor. On the basis of a very small number of
cases, rs6198 was suggested to be associated with PV and MF, but
not ET21. An association with MF, however, was conﬁrmed in a
subsequent larger study22. This SNP is not included on the SNP 6
platform and thus was not formally evaluated in our study.
However, we did not see any suggestion of an association with
other SNPs at NR3C1 in our stage-1 cohort, which consisted of
cases with ET.
The JAK2 and TERT SNPs had effects that were stronger in
JAK2V617F-positive cases, whereas rs4858647 (THRB-RARB) was
stronger in JAK2V617F-negative cases. Within JAK2V617F-negative
cases, the effect of rs9376092 (HBS1L-MYB) was markedly
stronger in cases with CALR and/or MPL mutations compared
with those that were triple negative. Overall, the three principal
loci (JAK2/TERT/MECOM) are estimated to have a combined
PAR of 51% for JAK2V617F-negative MPN. Fine mapping may
uncover some of the missing heritability, either by identifying
causal variants that are more strongly associated or by identifying
additional signals at these loci. Nevertheless, it is likely that there
are additional loci with equivalent or lesser effects that predispose
to MPN, which could be detected by larger follow-up studies. Our
preliminary analysis of the impact of the new associations on
clinical and biological parameters recorded for the PT-1 trial have
suggested only weak effects at best, but it remains to be
determined whether integration of these genetic variants into
risk models, together with that of somatically acquired mutations,
may enhance risk proﬁling and be clinically useful. Nevertheless,
identiﬁcation of genetic predisposition loci provides pointers
towards novel biological mechanisms that underlie MPN
development.
Some of the associations we identiﬁed are close to loci with
established credentials of relevance to MPN. The strongest novel
association was rs2201862, 153Kb downstream of MECOM
(MDS1 and EVI1 complex locus), which has been implicated in
megakaryopoiesis by several lines of evidence. First, a number of
alternatively spliced mRNAs are transcribed from this locus and
one of these (EVI1) is overexpressed in myeloid malignancies
with chromosome rearrangements, usually an inv(3)(q21q26) or
t(3;3)(q21;q26) that reposition a GATA2 enhancer at 3q21
downstream of MECOM at 3q36 (ref. 23). Affected cases
typically display abnormal megakaryocyte morphology and
elevated platelet counts24. Second, overexpression of EVI1
blocks terminal differentiation of bone marrow progenitor cells
to granulocytes25 but promotes megakaryocyte differentiation in
UT-7/GM cells26. Third, the genetic basis of most cases of TAR
(thrombocytopenia with absent radii) syndrome is a null allele of
Table 2 | Frequency of somatic mutations and subtype speciﬁc effects.
A. Frequency of somatic mutations in CALR and MPL
Cohort CALRNo. (%) MPLNo. (%) CALR and/or MPLNo. (No. double þve) Triple ve No. (%)
UK1 266 (51.2) 51 (9.8) 316 (1) 204 (39.2)
UK2 84 (43.3) 11 (5.7) 94 (1) 99 (51)
German & Austrian 136 (47.2) 83 (28.8) 217 (2) 69 (24)
Greek 95 (21.5) 14 (3.2) 109 (0) 333 (75.3)
UK3 168 (51.9) 29 (9) 197 (0) 127 (39.2)
Italian 322 (52.6) 56 (9.2) 377 (1) 234 (38.2)
B. Association and comparison according to JAK2V617F and either CALR and/or MPL
SNP JAK2V617Fve
PMETA (OR)
JAK2V617Fþve UK4
ET&PV PMETA (OR)
PBD CALRþ ve and/
orMPLþve PMETA
(OR)
Triple  ve
PMETA (OR)
PBD CALRþ ve
and/or
MPLþve versus
triple  ve
JAK2V617Fþve UK4
ET PMETA (OR)
JAK2V617Fþve UK4
PV PMETA (OR)
PBD
JAK2V617Fþve
ET versus
JAK2V617Fþve
PV
rs12339666 1.272 10 10 (1.34) 5.43 1062 (2.43) 2.82 10 18 1.299 108 (1.40) 0.0002 (1.28) 0.0266 5.344 10 13 (1.68) 1.286 10 75 (3.50) 2.452 10 11
rs2736100 1.728 10 5 (1.31) 1.92 10 21 (1.66) 0.0026 0.0003 (1.32) 0.0179 (1.26) 0.6555 8.179 10 12 (1.62) 3.153 10 14 (1.71) 0.3864
rs2201862 1.964 109 (0.82) 0.0368 (0.89) 0.3218 2.628 106 (0.82) 5.08 10 5 (0.83) 0.2237 0.1716 (0.91) 0.0733 (0.88) 0.9684
rs9376092 5.273 106 (1.18) 0.0566 (1.12) 0.4967 3.869 106 (1.24) 0.0493 (1.11) 4.487 10 7 2.62 106 (1.41) 0.0683 (0.87) 0.0004
rs4858647 1.393 10 5 (1.24) 0.6891 (1.04) 0.0146 0.0010 (1.23) 0.0072 (1.21) 0.1018 0.7167 (1.04) 0.8049 (1.03) 0.4167
(A) Number and percentage of cases with somatic mutations in CALR and MPL in each population. Cases with somatic mutations in CALR and MPL are described as double þ ve. Triple  ve refers to
cases without somatic mutation in JAK2, CALR and MPL. In cohorts with double positives, the percentage of cases will sum to just over 100. (B) PMETA and odds ratio (OR) from ﬁxed effects meta-
analyses in subsets of cases deﬁned by the somatic status of JAK2, CALR and MPL. PBD, Breslow–Day test P value.
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RBM8A coupled with a rare polymorphism that creates an EVI1
binding site at the RBM8A promoter, resulting in greatly reduced
levels of RMB8A expression27. Owing to a highly restricted
expression pattern in haematopoietic progenitors, we were unable
to determine whether rs2201862 inﬂuences MECOM expression;
however, mining of publicly available databases indicated that
this SNP, which is in a region of very low LD, co-localizes with a
DNAse1-hypersensitive site in the embryonic stem cell line h7-
hESC, suggesting it may correspond to a regulatory element with
enhancer-like activity.
Although rs9376092 did not reach genome-wide signiﬁcance in
JAK2V617F-negative cases alone, other data points to its
importance as a risk allele in MPN. This SNP maps to a well-
characterized region on chromosome 6q23 located 51Kb
centromeric of HBS1L and 75Kb telomeric of MYB. MYB
encodes a transcription factor present at high levels in immature
progenitors that plays an important role in progression through
key stages of haemopoiesis28. HBS1L encodes a GTP-binding
elongation factor that is involved in the regulation of a variety of
cellular processes, such as protein synthesis, cytoskeletal
trafﬁcking and signal transduction29. In healthy individuals,
diverse SNPs in the HMIP region between HBS1L and MYB were
initially found to be associated with hereditary persistence of fetal
haemoglobin30. Subsequent studies identiﬁed that HMIP SNPs
are associated with normal variation in platelet, monocyte and
erythrocyte counts as well as erythroid phenotype15,31–34. The
SNP identiﬁed by our GWAS, rs9376092, is also located in the
HMIP region and is in strong linkage disequilibrium with other
variants that tag this block. Recently, HMIP variation has also
been linked to the risk of developing Hodgkin’s lymphoma35.
Several studies have focused on the deﬁnition of HMIP as an
erythroid distal regulatory region. HMIP shows DNase I
hypersensitivity, GATA binding, RNA polymerase II interaction
and marked histone acetylation36–38. In erythroid progenitor cells
grown in liquid culture, HMIP variation correlated with both
HBS1L and MYB expression, but the effect was more pronounced
for HBS1L and only HBS1L expression correlated with elevated
levels of fetal haemoglobin39. However, the multiple genetic
associations described above indicate that HMIP inﬂuences other
myeloid lineages, suggesting that it may harbour multiple tissue-
speciﬁc enhancer elements. Indeed, we found that allelic variation
at rs9376092 was associated with differences in expression of both
ﬂanking genes in healthy individuals but most markedly with
MYB, with the risk allele linked to reduced MYB expression. We
also found that MYB expression is lower in JAK2V617F mutant
BFU-E from ET patients compared with wild-type BFU-E. These
observations are in agreement with previous ﬁndings that genetic
knockdown of Myb in mice induces a transplantable MPN that
closely resembles human ET16 and that MYB knockdown in
CD34þ human bone marrow cells promotes megakaryocyte
development40. Thus, our ﬁndings link a candidate risk SNP to
lower levels of MYB expression, which has been shown to
promote an ET-like disease in mice and megakaryocytic
development in humans. Strikingly, in JAK2V617F-positive cases
we ﬁnd that variation at rs9376092 is strongly linked to an ET
phenotype. Direct comparison of SNP frequencies between
JAK2V617F-positive ET and JAK2V617F-positive PV indicates
that the rs9376092 C allele is more common in ET (allelic w2
P¼ 7.5 10 7; Table 3), whereas comparison with controls
indicates that this SNP speciﬁcally increases the risk of ET (allelic
w2 P¼ 2.6 10 6; Table 2B), and there is a trend towards a
reduction in the risk of developing PV (allelic w2 P¼ 0.068) since
the effects are in the opposite direction for these two subtypes
(Table 2B). It is well established that homozygous JAK2V617F-
positive clones are much more prominent in PV than ET41, an
observation that is consistent with the suggestion that elevated
JAK2 signalling promotes an erythroid phenotype. The ﬁnding
that leukocyte counts in murine JAK2V617F retroviral-mediated
transfection/transplantation models differ in a strain-dependent
manner was the ﬁrst suggestion that host genetic factors may
inﬂuence the disease phenotype42. Here, we have identiﬁed
HBS1L-MYB as a locus outside JAK2 that inﬂuences the
phenotype of human MPN.
In conclusion, our study indicates that genetic variation at
multiple loci contributes to the risk of developing a MPN. The
functional basis for these associations is largely unknown, but we
have linked a candidate risk SNP at 6q26 to lower levels of MYB
expression and an ET phenotype. Further investigation will be
needed to understand how genetic variation at JAK2, MECOM,
TERT and other loci predispose to MPN.
Methods
Stage-1 discovery data set. Before quality control, the stage-1 cohort consisted of
571 cases of JAK2V617F-negative MPNs from the United Kingdom (referred to as
UK1), which comprise 556 with ET and 15 with PMF. Of these, 392 were sourced
from the UK Primary Thrombocythaemia 1 (PT-1) study, which included newly
diagnosed and previously treated patients, aged 18 years or over, who met the
Polycythemia Vera Study Group (PVSG) criteria for ET19. One hundred and one
are from the NCRI MPN sample bank at Addenbrookes Hospital, Cambridge. The
remaining cases (n¼ 78) were recruited from the NCRI MPN Study Group
members following clinical and morphological review to identify bona ﬁde MPN
cases. For stage-1 controls, the National Blood Service (NBS) cohort from the
Wellcome Trust Case Control Consortium (WTCCC2; n¼ 2674;
www.wtccc.org.uk) was used.
Replication cohorts. Five independent cohorts of JAK2V617F-negative MPN who
met the Polycythemia Vera Study Group or World Health Organization criteria for
ET or MF were used to validate signiﬁcant SNPs from stage-1 (Supplementary
Table 1). These cohorts consisted of 198 cases from the United Kingdom and 2,706
controls from the WTCCC2 1958 British Birth Cohort (BBC, Stage-2.1), 286 cases
from a combination of Austrian43 (n¼ 99) and German cases (n¼ 187) and 1,805
Bavarian controls from the German Cooperative Health Research in the Region of
Augsburg cohort (KORA F4; Stage-2.2)44, 460 Greek cases and 1,196 locally
recruited Greek controls (Stage 2.3), 328 cases from the United Kingdom and 2,800
controls from a combination of controls from BBC (n¼ 2706) and the United
Kingdom (n¼ 94) (Stage-3.1), and 637 Italian cases and 1,608 Italian controls
(Stage-3.2) from a combination of controls from the Invecchiare in Chianti study
(InCHIANTI; n¼ 1210)45, and a series of locally recruited Italian controls
(n¼ 398). To further validate our ﬁndings, 406 UK cases with elevated levels of
platelets and/or erythrocytes and a reactive cause were identiﬁed. These reactive
cases mimic MPN but are non-clonal and were used as a negative control by
comparison with 2,706 controls from the BBC (Stage-3.3).
Table 3 | Comparison between ET and PV subtype in JAK2V617F positive cases.
SNP Gene Alleles PV MAF ET MAF P value OR (CI)
rs12339666 JAK2 T/G 0.5627 0.3815 4.788 10 16 2.09 (1.75–2.49)
rs2201862 MECOM T/C 0.4817 0.489 0.7523 0.97 (0.81–1.17)
rs9376092 HBS1L-MYB A/C 0.2495 0.3507 7.475 10 7 0.62 (0.51–0.75)
rs4858647 THRB-RARB A/C 0.1000 0.1012 0.9286 0.99 (0.74–1.32)
rs2736100 TERT C/A 0.6426 0.6303 0.5663 1.06 (0.88–1.27)
P-value, odds ratio (OR), and 95% conﬁdence interval (CI) for comparison of JAK2V617F-positive PV (n¼ 505) and ET cases (n¼499) using allelic w2-test.
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To determine whether SNPs with signiﬁcant replication in one or more of the
ﬁve follow-up cohorts are associated exclusively with JAK2V617F-negative MPN,
two independent cohorts of consisting of 556 ET and PMF JAK2V617F-positive
MPN cases and 556 PV JAK2V617F-positive MPN cases from the United Kingdom
were genotyped and compared with 2,706 controls from the BBC (Stage-3.4 and 3.5
Supplementary Table 1). The study was approved by the following Internal Review
Boards and/or ethics committees: National Research Ethics Service (UK)
Committee South West; London Multicentre Research Ethics Committee;
Cambridgeshire4 Research Ethics Committee; Trent Research Ethics Committee;
Ethics Committee of the Biomedical Research Foundation of the Academy of
Athens; Comitato Etico, Azienda Ospedaliero-Universitaria Careggi, Firenze;
Comitato di Bioetica, Fondazione IRCCS Policlinico San Matteo, Pavia; Ethic
committee of the Bavarian State Chamber of Physicians; Ethic committee of the
University of Ulm; Medizinische Ethikkommission II der Medizinischen Fakulta¨t
Mannheim; Ethikkommission der Medizinischen Universita¨t Wienand informed
consent was obtained from participants according to the Declaration of Helsinki.
Genotyping. The stage 1 cases were genotyped by AROS Applied Biotechnology
(Aarhus, Denmark) using Affymetrix SNP6 arrays. To reduce genotyping errors
and ensure harmonization of genotype calls across plates, the raw data (cel ﬁles)
were pooled and the Birdseed v2 algorithm in Affymetrix’s genotyping console was
used to determine genotypes. The stage 1 controls were previously genotyped by
the WTCCC using Affymetrix SNP6 arrays and the CHIAMO algorithm to
determine genotypes. Excluding the WTCCC2 controls, KORA controls and
Austrian cases, the replication cohorts were genotyped by LGC Genomics (for-
merly KBiosciences, Hoddesdon, UK). In the initial validation round (Stage 2), 203
SNPs were genotyped and ﬁve of these SNPs were selected for genotyping in the
second validation round (Stage 3). The Austrian cases, Bavarian controls and
WTCCC2 controls were previously genotyped using Affymetrix SNP6 arrays.
Stage-3.4 and stage-3.5 JAK2V617F-positive MPN cases from the United Kingdom
were genotyped using the Illumina Human OmniExpressExome v1.2 platform by
Gen-Probe Life Sciences Ltd (Wythenshawe, UK).
Quality control for genotyping. Quality control of the stage-1 genotypes involved
the removal of samples with poor resolution of SNP clusters (n¼ 12 samples with
contrast QC o0.4), SNPs with MAF o0.01, SNPs without observations for all
three genotypes, SNPs and samples with 410% missing genotypes. A number of
measures were used to control for poor genotyping: ﬁrst, SNPs with signiﬁcant
deviations from Hardy–Weinberg equilibrium (HWE) in control samples (Exact
test P-value r0.001) were removed. Since the cases and controls at stage-1 were
not genotyped at the same time, we also removed SNPs with extreme deviation
from HWE in cases (Exact test P-value r1 10 10) and SNPs with an average
genotyping conﬁdence call over all cases that were 42 s.d. values worse than the
mean over all SNPs to control for potential genotyping errors in cases. To further
control for poor genotyping, SNPs with allele frequencies that were signiﬁcantly
different between the two WTCCC2 control cohorts (NBS and BBC) and Cauca-
sian controls from HapMap were also removed. Finally, SNPs located on non-
autosomal chromosomes were removed and CNVs were not considered. A total of
266,988 SNPs were removed from the discovery cohort during these QC steps
leaving observed genotypes at 642,633 SNPs for analysis.
Pairwise identity by state scores (IBS) were used to test the stage-1 samples for
cryptic relatedness and nine individuals with IBS scores486% were excluded from
the stage-1 samples. These IBS scores were also used to perform a multi-
dimensional scaling analysis (MDS) to identify ethnic outliers when referenced
against the HapMap populations. On this basis, 26 of the stage-1 samples whose
genotypes did not concur with a European ancestry were removed. The remaining
cases clustered tightly with the WTCCC2 controls in the MDS plot, which
demonstrates that our cases and controls are ethnically compatible (Supplementary
Fig. 6). After these quality control procedures 524 cases (from 571 genotyped) and
2,674 controls remained for analysis in the discovery cohort. Of the 556 ET and
PMF JAK2V617F-positive MPN cases (stage-3.4) and 556 PV JAK2V617F-positive
MPN cases (stage-3.5), 499 and 505 remained for analysis. All quality control steps
were performed using PLINK46.
To increase the resolution of the stage 1 data, additional SNPs were imputed
using MACH 1.0 (http://www.sph.umich.edu/csg/abecasis/MACH/index.htm) and
reference data from HapMap phase 2 in the form of SNP genotypes and phased
haplotypes from the CEPH population (Utah residents with ancestry from
northern and western Europe, CEU). The imputed data were quality controlled by
excluding SNPs with a posterior probability r0.9, MAF o0.01, 410% missing
genotypes, or with signiﬁcant deviation from HWE (Exact test P valuer1 10 10
in cases or Exact test P valuer0.001 in controls). Following this process, a total of
1,455,406 imputed SNPs remained for analysis. For the Stage-3.4 cases, the
genotypes of rs9376092, rs4858647 and rs2736100 are included on the Illumina
Human OmniExpressExome v1.2 platform and were therefore determined directly;
rs12339666 and rs2201862 were determined by imputation.
Statistical analysis. We used allelic w2 to compare allele frequencies between cases
and controls and calculate odds ratios (ORs) and 95% conﬁdence intervals (CIs).
To examine the possibility of confounding factors in our stage-1 data, such as
population stratiﬁcation and separate genotyping of cases and controls, we used the
qqnorm and qqplot procedures in R47 to construct a quantile-quantile (Q-Q) plot
of observed and expected P values under the null distribution (Supplementary
Fig. 2). Manhattan plots were generated using HaploView 4.2 (ref. 48), and regional
plots were generated using LocusZoom49.
The power of our stage-1 cohort to detect markers associated with the risk of
developing MPNs was estimated using the genetic power calculator12 with values of
524 cases and 2,674 controls, and an age standardized disease prevalence of one per
5,000 European persons50. Modest values of genotype relative risk (1.1–2.0) were
used and it was assumed that the causal allele had been tagged with D0 ¼ 0.8 and
controls are unselected. In general, study power is diminished by lower causal allele
frequency, and so a range of conservative estimates (0.05–0.3) for this value were
used.
GWA studies are prone to detection of false positives and our stage-1 sample
size is modest. To ensure that the most promising signals were taken through to
stage-2, we therefore selected SNPs on the basis of the following criteria rather than
signiﬁcance alone. First, a ‘clumping’ procedure46 was used to select 120 SNPs with
allelic w2 P values r0.001 and support from correlated SNPs (r2 Z0.5, within
500 kb, and allelic w2 P value r0.01). Second, 22 SNPs were selected that have
allelic w2 P values r0.02 and are within 500 kb of loci associated with normal
variation in platelet number (PLT) and or platelet volume (MPV)14. An additional
11 SNPs with allelic w2 P valuesr0.0007 were chosen on the basis of their location
within or near genes with functional relevance. Finally, 50 SNPs with allelic w2
P values r0.0002 and without correlated SNPs (r2 Z0.5) were also selected. For
regions with multiple SNPs with signiﬁcant association, the most signiﬁcant SNP
was selected as the lead along with any other SNP(s) that were not in high LD with
the lead SNP (r2r0.6). Using these selection techniques a total of 203 SNPs were
identiﬁed.
A ﬁxed effects inverse variance-weighted meta-analysis of the stage-1 and stage-
2 results was used to select ﬁve SNPs with meta-analysis P values r0.001 and
effects in the same direction for further analysis at stage-3. The same methodology
was used to determine the ﬁnal effect size and signiﬁcance by combining the results
from the six JAK2V617F-negative cohorts. The metan module in STATA v11.0
(ref. 51) was used to perform these meta-analyses under the assumption of one true
effect size (odds ratio) and that any differences in observed effects between studies
are due to sampling error. Two methods were used to estimate the between-study
heterogeneity, these are the w2-based Cochran’s Q statistic and the I2 statistic,
which describe the percentage of variation across studies that is due to
heterogeneity rather than chance52.
To assess the impact of our ﬁndings at a population level, we computed
population attributable risks (PAR), which estimate the proportion of MPN cases
that can be attributed to each polymorphism. We calculated this as, PAR¼ (x 1/
x)100, where x¼ (1 p)2þ 2p(1 p)OR1þ p2OR2, p is the frequency of the risk
allele in the control cohort, and OR1 and OR2 are the genotypic ORs associated
with heterozygosity and homozygosity, respectively, and relative to common
homozygotes53. A combined PAR was also calculated as
PAR¼ 1 (1 PAR1)(1 PAR2)y(1 PARn) incorporating all risk factors.
To determine whether SNPs with signiﬁcant replication were associated
exclusively with JAK2V617F-negative MPNs, a Breslow–Day test was used to
assess the homogeneity of effect sizes (ORs) among the V617F negative and
positive cohorts (Breslow–Day P values o0.05 were considered statistically
signiﬁcant). The Breslow–Day method was also used to assess the homogeneity
of effect sizes (ORs) in cases with or without somatic mutations in either
CALR or MPL.
We considered the possibility that the observed associations might arise as a
consequence of clonal somatic changes in the MPN cases. Although it is
theoretically possible that the constitutional genotypes of the intragenic SNPs we
identiﬁed might be altered by somatic point mutations, this is clearly extremely
unlikely in a disorder for which the rate of somatic mutation is known to be low
(median number of somatic mutations in ET and PV¼ 6.5/exome and for MF 13/
exome 3). More plausible is the possibility that constitutional genotypes might be
altered by small regions of loss of heterozygosity (LOH) that are below the limit of
detection of SNP arrays. LOH in the majority of cells would result in germline
heterozygous SNPs being scored as homozygous. If the LOH was recurrent and
occurred randomly with respect to SNP genotype then it would have no effect on
the allele frequency. For example, a SNP with a MAF of 50% would normally be
expected to result in a genotype distribution of 25% a/a, 50% a/b and 25% b/b.
Recurrent somatic LOH in say 20% of cases would result in an apparent genotype
distribution of 30% a/a, 40% a/b and 30% b/b. The MAF is still 0.5, and thus there
is no effect on the association study. If, however, small deletions/aUPD were not
random with respect to SNP genotype (for example, if they were part of a particular
haplotype that conferred a selective advantage when lost or gained) then we would
expect to see distortions in genotypes that could potentially affect the GWAS
results. In the example above, if a hemizygous a/- or homozygous a/a genotype had
a selective advantage over a/b, then a recurrent somatic deletion/aUPD in 20% of
cases would result in an apparent genotype distribution of 35% aa, 40% ab and
25% bb. The apparent MAF is 0.45 and thus could be picked up by the GWAS
if the effect was large enough. However, in both instances the genotypes would be
skewed away from the expected Hardy–Weinberg equilibrium (Exact test P
value¼ 3.52 10 6 and exact test P value¼ 1.45 10 6 for 20% LOH occurring
randomly or selecting a/a genotype, respectively). All our SNPs showed close
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agreement with expected Hardy–Weinberg distribution: as indicated in
Supplementary Table 7, none showed an exact test P valuer0.05 in our data. If we
simulate LOH randomly affecting just 10% of cases the exact test P values change
markedly (ﬁnal column): 5/6 deviate signiﬁcantly from expected at exact test
Pr0.05 and 3/6 deviate signiﬁcantly at exact test Pr0.001. The lack of any
signiﬁcant deviation strongly suggests that clonal changes have not contributed to
the signiﬁcance of SNPs in this study.
Statistical analysis of risk variants in PT-1. For continuous variables, analyses
comparing diagnostic variables and genotype were performed using linear models,
correcting for JAK2 status and using the dosage of alleles as the predictor variable
for the SNP of interest. For categorical variables, the analysis used the w2-test for
trend across the dosage of alleles of the SNP of interest. Clinical outcome was
assessed by w2-tests for events preceding diagnosis and log-rank test for events after
trial entry. Linear mixed effect models were used to assess the relationships
between the SNP and response of blood counts to therapy.
Chromosomal abnormalities identiﬁed by analysis of SNP array data. To
identify regions of acquired uniparental disomy (aUPD) and indels, PennCNV54
and Affymetrix Power Tools (APT www.affymetrix.com/support/developer/
powertools/index.affx) were used to convert the raw CEL ﬁles into a normalized
signal intensity ﬁle that were comparable in terms of raw signal intensity
distributions. Log R Ratio (LRR) and B Allele Frequency (BAF) were calculated for
each marker in each individual using the allele-speciﬁc signal intensities from the
normalized signal intensity ﬁle. BAF segmentation55 was used to exclude non
informative homozygous SNPs (BAF 40.9 or BAF o0.1) and SNPs where the
absolute difference in BAF between preceding or succeeding SNPs was greater than
0.6. Mirrored BAF (mBAF) values were calculated by reﬂection at 0.5, and a
circular binary segmentation (CBS) algorithm was used to identify regions of
similar allelic proportions with mBAF above a threshold of 0.56. Finally, regions of
allelic imbalance were compared with log R Ratios to determine whether they were
indels or copy number neutral aUPD.
Screening JAK2, CALR and MPL for somatic mutations. Samples were screened
JAK2V617F using a range of techniques employed at the recruiting centres. Muta-
tions in CALR were detected using fragment analysis PCR and characterized using
Sanger sequencing. For fragment analysis, one primer was labelled with either 6-
carboxyﬂuorescein (6-FAM) or 6-carboxyﬂuorescein hexachloride (HEX). PCR
was performed using 1.25U HotStar Taq (Qiagen, Crawley, UK), 1 x HotStar Taq
buffer, 1.5mM MgCl2, 200 mM dNTPs, 0.5 mM each primer (CALR_FA_F and
CALR_FA_R, primers listed in Supplementary Table 4), 20–40 ng DNA in a 25 ml
reaction. Cycling conditions were 95 C for 10min, 30 cycles of 95 C for 1min,
60 C for 1min, 72 C for 1min, followed by 72 C for 30min. Products were
diluted between 1/500 and 1/1,000 in sterile water and resolved by capillary gel
electrophoresis, by sizing on a 3130 Genomic Analyser (Life Technologies, Paisley,
UK). Results were analysed using GeneMarker software version 1.85 (SoftGenetics,
State College, PA, USA) and analysed on the blue (FAM) or green (HEX) channel.
For Sanger sequencing, PCR was carried out using primers (CALR_seq_F and
CALR_seq_R) and following identical reaction and cycling conditions to that used
for fragment analysis, apart from a ﬁnal extension at 72 C for 10min. Sequences
were analysed using Mutation Surveyor 3.1 software (SoftGenetics, State College,
PA, USA).
Speciﬁc pyrosequencing assays were used to detect MPL W515 mutations,
following standard PCR, cycling and procedural methods described previously56.
For each sample, primers designed to amplify the region in question (MPL_pyro_F
and MPL_pyro_R, sequences listed in Supplementary Table 4) were used to create
a biotinylated PCR product, which was then used in a pyrosequencing reaction
using a sequencing primer (MPL_pyro_seq) for both the MPL W515L mutation
and the MPL W515K mutation (sequences to analyse were 50-GTKGCAGTTTCC
TGCACACTACAGGTAC-30 and 50-GTRGCAGTTTCC TGCACACTACAGG
TAC-30 , respectively). Pyrosequencing PCR products for MPL were also Sanger
sequenced to identify rarer mutations using the reverse primer, following
conditions outlined above.
We note that the frequency of MPL and CALR mutations varies between
cohorts (Table 2A). Speciﬁcally, the frequency of somatic CALR mutations varied
between 22 and 53% (average 45%), while somatic mutations in MPL were seen in
3 to 29% (average 11%) of cases. Concerning MPL, the German/Austrian cohort
was not sequential and included a substantial number of MPL-mutated cases that
were speciﬁcally collected for a previous study10. As for CALR, the mutation
frequency was lower than that reported previously2,3 for all cohorts and
substantially lower for the Greek cases. We believe that these differences are likely
to result from the well known difﬁculty in accurately deﬁning JAK2V617F-negative
ET in routine practice by exclusion of all potential causes of reactive
thrombocytosis57. In addition, we cannot exclude the possibility that the frequency
of CALR mutations might vary between different MPN populations.
Gene expression analysis. To avoid potential confounding effects of undeﬁned
somatic mutations, peripheral blood (PB) samples were obtained from anonymised
healthy individuals. Mononuclear cells were cultured in methylcellulose medium
(H4434; Stem Cell Technologies, Vancouver, Canada) at a density of 2 105 cells
per ml, following the manufacturer’s instructions. Colonies comprising a minimum
of 100 cells were characterized based on morphology as CFU-GM, CFU-GEMM,
CFU-E or BFU-E, as described by Stem Cell Technologies. For each individual,
colonies were plucked and pooled according to morphology, into monocyte/
granulocyte (containing CFU-GM and CFU-GEMM) and erythroid colonies
(containing CFU-E and BFU-E). Cells were washed in PBS, lysed in trizol and RNA
extracted and reverse transcribed into cDNA using random hexamer primers
following standard procedures. MYB and HBS1L expression was measured in
duplicate using TaqMan assays (Applied Biosystems) and a Corbett Rotor Gene
6000 (Corbett Life Science, Sydney, Australia).
Relative MYB (two alternatively spliced isoforms) and HBS1L expression for
each target were normalized to GUSB expression (Supplementary Tables 4 and 5)
values using the delta-delta Ct method, as described by Pfafﬂ et al.58 Test samples
were placed into two groups according to HMIP risk allele status, either carrying
one or two risk alleles (AA/AC) or no risk alleles (CC). Complementary DNA from
two separate normal granulocyte samples previously deﬁned as carrying the AC
and CC risk allele genotype was used as calibrator samples to test for normality of
expression distribution, and serial dilutions of cell line K562 cDNA was used to
control for Q-PCR efﬁciency. For each sample, expression values were compared
with the equivalent calibrator control, that is, the AA/AC test group was
normalized to the AC calibrator control, and the CC test group was normalized to
the CC calibrator control. The Mann–Whitney test was used to evaluate the
difference in MYB and HBS1L expression levels, comparing normalized expression
values for those that were grouped as AA/AC versus those grouped as CC, for each
of the PB granulocyte, BFU-E and CFU-GM cell subtypes. Fold difference in gene
expression was determined by subtracting the median normalized expression level
of the CC group by that of the AA/AC group, for each cell type subset.
Functional annotation of candidate genes. For identiﬁcation of candidate genes
and previous trait associations, we considered the nearest gene, and any other gene
located within 500 kb of the sentinel SNP to be a candidate for mediating pre-
disposition to MPN. Genomic regions carrying risk loci and candidate genes were
investigated for other trait associations by inspecting a database of all SNP asso-
ciations that reach genome-wide signiﬁcance, curated by the National Human
Genome Research Institute GWAS catalogue59. Only associations potentially
relevant to haematopoiesis were considered.
To predict functional effects we used HaploReg60 to identify SNPs linked to the
sentinel SNPs (r240.8 in Europeans from the 1000 Genomes Project) and, on the
basis of data from the Encyclopedia of DNA Elements (ENCODE)61 and the NHRI
Roadmap Epigenomics Mapping Consortium62, to annotate them with respect to
(i) histone modiﬁcations, (ii) DNaseI hypersensitivity, (iii) transcription factor
binding, (iv) disruption of regulatory motifs and (v) conservation across mammals
estimated by GERP and SiPhy. To further investigate the sentinel and linked
variants we used RegulomeDB63 to assign functionality scores on the basis of data
from Gene Expression Omnibus (GEO), ENCODE and published literature. A
RegulomeDB score of 5 and 6 indicates there is minimal evidence for functional
activity. Finally, we investigated whether our index and linked SNPs overlapped
with regions of nucleosome depletion generated by formaldehyde-assisted isolation
of regulatory elements (FAIRE-seq), as depleted regions have been shown to have
greater epigenetic activity and mark the presence of functional variants that alter
the underlying DNA sequences, resulting in different binding afﬁnities for
transcription factors64. For this we obtained ﬁltered and binned BED ﬁles
containing FAIRE-seq data from primary human megakaryocytes and
erythroblasts65, and intersected SNP positions with FAIRE regions to look for
regions of colocalisation.
All candidate genes were investigated for expression in hematopoietic cells, by
interrogating browsers of gene expression proﬁles generated in puriﬁed progenitors
of different lineages of the human haematopoietic system (HaemAtlas66 and
HemaExplorer67) and a recently published data set68. To investigate the
relationship between the sentinel SNPs and gene expression levels, two expression
quantitative trait (eQTL) browsers were used that curate derived from
immortalized lymphoblastoid cell lines and primary monocytes; an eQTL browser
hosted by the Pritchard laboratory18 and GENEVAR69.
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